PhenoPath, PLLC

Diagnoses you can count on®

PhenoPath, PLLC is a physician-owned specialty pathology practice and reference laboratory providing diagnostic and contract research services to pathology and oncology practices, hospitals, biopharmaceutical companies and research institutions in the U.S., Canada and around the world.

PhenoPath’s test menu includes a broad array of state-of-the-art immunohistochemistry, flow cytometry, fluorescence in situ hybridization and molecular assays as well as chromosome analysis.

PhenoPath now offers EGFR mutation testing using cell-free DNA isolated from plasma. Please see the links below for more information:

Please see Biomarker Testing for Checkpoint Inhibitors for more information on PD-L1 22C3, PD-L1 28-8 and PD-L1 SP142.

Latest News

  • Phenomena v19.2 (Summer 2016)

    PD-L1 Update, Flow Cytometry, Kappa / Lambda ISH, Molecular Testing in Colorectal Carcinoma, Webinar, and more!

    Read More »
  • PD-L1 IHC 22C3 pharmDx

    PhenoPath is proud to announce the release of FDA-approved PD-L1 IHC 22C3 pharmDx, for the semi-quantitative assessment of PD-L1 expression in non-small...

    Read More »
  • Roche cobas® EGFR Mutation Test

    PhenoPath is pleased to offer the Roche cobas® EGFR Mutation Test (v2), the only FDA-approved IVD assay for the detection of T790M, Exon 19...

    Read More »

PhenoPath, PLLC

About PhenoPath

Vision

Medical Staff

Executive Staff

Licensing & Accreditation

Careers

Test Menu

Technologies

Diagnostic Services

Clinical Setting

Educational Media

Contact Diagnostic Services

BioPharma Services

Clinical Trial Services

R & D Services

QAU

IT

Contact BioPharma Services

News & Info

Company News

Newsletters

Publications

Upcoming Events

Contact Us

Dept. Inquiries

Submit a Case

Order Supplies

Holidays

Patients